iOS app Android app

Fda Biosimilars

Obamacare Drug Provision Sparks Savings and Competition

Jessica Stone | Posted 11.02.2015 | Politics
Jessica Stone

While Obamacare stories often focus on the law's insurance premium impact, a lesser known provision of the law is starting to save some patients money and provide more choice in treatments.

U.S. Pharma Industry Getting Ready for a Shake Up

Jessica Stone | Posted 06.30.2015 | Business
Jessica Stone

In the coming weeks, a single drug will revolutionize the U.S. pharmaceutical industry. Zarxio, a drug that reduces infections caused by chemotherapy, is about to become the very first biosimilar drug sold in the United States.

Approved Pathway for Biosimilars Must Be Patient-Focused

Eva M. Clayton | Posted 08.25.2012 | Healthy Living
Eva M. Clayton

The U.S. pharmaceutical industry has worked hard to become an international leader in the production of biotech drugs. But as the nation introduces these medicines, we need to ensure that safety protocols are in place -- so that every patient has the opportunity to get healthy.

Are Unsafes Drugs An 'Acceptable Risk?' FDA Should Say 'No!'

John Horton | Posted 05.25.2011 | Home
John Horton

As a matter of common sense, the FDA's process for biosimilars shouldn't sacrifice patient safety.